0001209191-21-065839.txt : 20211119 0001209191-21-065839.hdr.sgml : 20211119 20211119165920 ACCESSION NUMBER: 0001209191-21-065839 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211117 FILED AS OF DATE: 20211119 DATE AS OF CHANGE: 20211119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROBINS HARLAN S CENTRAL INDEX KEY: 0001780851 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 211429072 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVE E STE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-11-17 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001780851 ROBINS HARLAN S 1165 EASTLAKE AVENUE E SEATTLE WA 98109 0 1 0 0 Chief Scientific Officer Common Stock 2021-11-17 4 M 0 3700 6.55 A 73060 D Common Stock 2021-11-17 4 S 0 3700 32.05 D 69360 D Common Stock 2021-11-18 4 M 0 300 6.55 A 69660 D Common Stock 2021-11-18 4 S 0 300 31.36 D 69360 D Stock Option (Right to Buy) 6.55 2021-11-17 4 M 0 3700 0.00 D 2028-02-07 Common Stock 3700 285100 D Stock Option (Right to Buy) 6.55 2021-11-18 4 M 0 300 0.00 D 2028-02-07 Common Stock 300 284800 D These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.45 to 32.36, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.00 to 31.76, inclusive. The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Harlan Robins by Eric Billings, Attorney-in-Fact 2021-11-19